c-Met receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Flow focusing is a usually passive formation method that involves the dispersed phase flowing to meet the continuous phase typically at an angle (nonparallel streams) then undergoing a constraint that creates a droplet. This constraint is generally a narrowing in the channel to create the droplet though symmetric shearing, followed by a channel of equal or greater width. As with cross-flowing, the continuous phase flow rate is typically higher than the dispersed phase flow rate. Decreasing the flow of the continuous phase can increase the size of the droplets. Flow focusing can also be an active method with the constraint point being adjustable using pneumatic side chambers controlled by compressed air. The movable chambers act to pinch the flow, deforming the stream and creating a droplet with a changeable driving frequency. Droplet size is usually around several hundred nanometers with a CV of less than 3% and a rate of up to several hundred Hz to tens of kHz.
Early bulbs were laboriously assembled by hand. After automatic machinery was developed, the cost of bulbs fell. Until 1910, when Libbey's Westlake machine went into production, bulbs were generally produced by a team of three workers (two gatherers and a master gaffer) blowing the bulbs into wooden or cast-iron molds, coated with a paste. Around 150 bulbs per hour were produced by the hand-blowing process in the 1880s at Corning Glass Works. The Westlake machine, developed by Libbey Glass, was based on an adaptation of the Owens-Libbey bottle-blowing machine. Corning Glass Works soon began developing competing automated bulb-blowing machines, the first of which to be used in production was the E-Machine.
==== Urquía Carreño ejected from the Grand Lodge ==== On March 24, 2024, the Upper House of the Grand Lodge of Cuba was scheduled to convene, and as Urquía Carreño was preparing to convene the session, a rise of 300 men chanting rang through the chamber, and echoed off the walls: "Get out of here thief! You scoundrel! You traitor! Out thief! Out scoundrel! Out traitor! Out thief! Out scoundrel! Out traitor!" Urquía Carreño refused to leave the room at first, but the chanting grew louder, and everyone present demanded his resignation. Urquía Carreño told them that he would complain to the Registry of Associations of the Ministry of Justice, but one of the Masters reminded him that they had no authority in that room. Urquía Carreño did leave the room, and once he had done so, the Upper House of the Grand Lodge elected former Grand Master Ernesto Zamora Fernández (who had served as Grand Master during the protests in 2021) as interim President of the Upper House of the Grand Lodge. Zamora Fernández took the chair, and declared that all decrees and declarations that had ever been issued since January 25 were considered void, including the referral of all those individuals of whom he had sent up to the Supreme Court.
Sources: en.wikipedia.org
== Background == The 1988 Convention was introduced following the political and sociological developments in the 1970s and 1980s. The growing demand for cannabis, cocaine, and heroin for recreational purposes, mostly in the developed world, triggered an increase of illicit production in geographical areas where cannabis, coca, and opium had been traditionally cultivated. With the rising size of the illicit drug trade, international drug trafficking became a multibillion-dollar business dominated by criminal groups, providing grounds for the creation of the 1988 Convention and the consequential escalation of the war on drugs. The Preamble notes that previous enforcement efforts have not stopped drug use, warning of "steadily increasing inroads into various social groups made by illicit traffic in narcotic drugs and psychotropic substances." It cautions that the drug trade and related activities "undermine the legitimate economies and threaten the stability, security and sovereignty of States." The sense of urgency is underscored by the image of innocent boys and girls being exploited:
Phalen's maneuver. Performed by fully flexing the wrist, then holding this position and awaiting symptoms. A positive test results in paresthesia in the median nerve distribution within sixty seconds. Tinel's sign is performed by lightly tapping the median nerve just proximal to flexor retinaculum to elicit paresthesia. Durkan's test, carpal compression test, or applying firm pressure to the palm over the nerve for up to 30 seconds to elicit paresthesia. The hand elevation test, performed by lifting both hands above the head. Paresthesia in the median nerve distribution within 2 minutes is considered positive. Diminished threshold sensibility (the ability to distinguish different amounts of pressure) can be measured using Semmes-Weinstein monofilament testing. This test establishes impaired or loss of sensation. Electrodiagnostic testing including electromyography, and nerve conduction studies can objectively measure and verify median neuropathy. Ultrasound can image and measure the cross-sectional diameter of the median nerve, which has some correlation with CTS. The role of ultrasound in diagnosis—just as with electrodiagnostic testing—is a matter of debate. Data suggests that electrodiagnostic testing cannot detect the presence of CTS in 16% to 34% of people who have the condition. The role of confirmatory electrodiagnostic testing is controversial. The goal of electrodiagnostic testing is to compare the speed of conduction in the median nerve with conduction in other nerves supplying the hand.
The charge-to-mass ratio (Q/m) of an object is, as its name implies, the charge of an object divided by the mass of the same object. This quantity is generally useful only for objects that may be treated as particles. For extended objects, total charge, charge density, total mass, and mass density are often more useful. Derivation:
Sources: en.wikipedia.org
=== Economic return === In 2000, the Joint Economic Committee of Congress reported NIH research, which was funded at $16 billion a year in 2000, that some econometric studies had given a rate of return of 25 to 40 percent per year by reducing the economic cost of illness in the US. It found that of the 21 drugs with the highest therapeutic impact on society introduced between 1965 and 1992, public funding was "instrumental" for 15. As of 2011, NIH-supported research helped to discover 153 new FDA-approved drugs, vaccines, and new indications for drugs in the 40 years prior. One study found NIH funding aided either directly or indirectly in developing the drugs or drug targets for all of the 210 FDA-approved drugs from 2010 to 2016. In 2015, Pierre Azoulay et al. estimated $10 million invested in research generated two to three new patents.
== History == In literature from ancient Rome there are complaints of foul air, while in 1273 the inhabitants of London were discussing the prohibition of coal burning to improve air quality. However, the measurement and analysis of aerosols only became established in the second half of the 19th century. In 1847 Henri Becquerel presented the first concept of particles in the air in his condensation nuclei experiment and his ideas were confirmed in later experiments by Coulier in 1875. These ideas were expanded on between 1880 and 1890 by meteorologist John Aitken who demonstrated the fundamental role of dust particles in the formation of clouds and fogs. Aitken's method for aerosol analysis consisted of counting and sizing particles mounted on a slide, using a microscope. The composition of the particles was determined by their refractive index. In the 1920s aerosol measurements, using Aitken's simple microscopic method, became more common place because the negative health effects of industrial aerosols and dust were starting to be recognized by health organizations. Technological and instrumentation advancements, including improved filters, led to improvement in the aerosol measurement methods in the 1960s. The introduction of polycarbonate filters, called nucleopore filters, enhanced the collection, storage, and transportation of samples without disturbing the physical and chemical state of the particles. On-line aerosol measurements methods took a little longer than off-line to be developed and perfected. It wasn't till 1973 with W.D.
With the advent of digital inverter compressors, the energy consumption is even further reduced than a single-speed induction motor compressor, and thus contributes far less in the way of greenhouse gases. The energy consumption of a refrigerator is also dependent on the type of refrigeration being done. For instance, Inverter Refrigerators consume comparatively less energy than a typical non-inverter refrigerator. In an inverter refrigerator, the compressor is used conditionally on requirement basis. For instance, an inverter refrigerator might use less energy during the winters than it does during the summers. This is because the compressor works for a shorter time than it does during the summers. Further, newer models of inverter compressor refrigerators take into account various external and internal conditions to adjust the compressor speed and thus optimize cooling and energy consumption. Most of them use at least 4 sensors which help detect variance in external temperature, internal temperature owing to opening of the refrigerator door or keeping new food inside; humidity and usage patterns. Depending on the sensor inputs, the compressor adjusts its speed. For example, if door is opened or new food is kept, the sensor detects an increase in temperature inside the cabin and signals the compressor to increase its speed till a pre-determined temperature is attained. After which, the compressor runs at a minimum speed to just maintain the internal temperature. The compressor typically runs between 1200 and 4500 rpm.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.